Current drug screening methods, such as MTT assays, offer limited insights into cellular mechanisms and drug modes of action. Ethical and regulatory changes are reducing in vivo experiments, increasing the need for advanced in vitro tools. Genetically encoded biosensors provide real-time, detailed monitoring of cellular responses, enhancing drug screening efficiency and effectiveness. Our studies demonstrate their value in understanding nitric oxide dynamics in cardiovascular pharmacology and assessing iron supplement efficacy under physiological oxygen conditions. Integrating these biosensors into drug screening protocols can significantly improve the development of safer and more effective therapeutics.
No ethical issues are required for this study.
Primary Language | English |
---|---|
Subjects | Cardiovascular Medicine and Haematology (Other) |
Journal Section | Letter to Editor |
Authors | |
Early Pub Date | August 15, 2024 |
Publication Date | |
Submission Date | August 7, 2024 |
Acceptance Date | August 14, 2024 |
Published in Issue | Year 2024 Volume: 13 Issue: 2 |